Riluzole–Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis

Thumbnail
Publication date
2018-06-14
Author
Sweeney, J.B.
Rattray, Marcus
Pugh, V.
Powell, L.A.
Keyword
Motor neuron disease
Primary cortical neurons
Riluzole
Amyotrophic lateral sclerosis (ALS)
Triazoles
Neuroprotective activity
Rights
© 2018 ACS. This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Medicinal Chemistry Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acsmedchemlett.8b00103
Peer-Reviewed
n/a

Metadata
Show full item record
Abstract
Despite intense attention from biomedical and chemical researchers, there are few approved treatments for amyotrophic lateral sclerosis (ALS), with only riluzole (Rilutek) and edaravone (Radicava) currently available to patients. Moreover, the mechanistic basis of the activity of these drugs is currently not well-defined, limiting the ability to design new medicines for ALS. This Letter describes the synthesis of triazole-containing riluzole analogues, and their testing in a novel neuroprotective assay. Seven compounds were identified as having neuroprotective activity, with two compounds having similar activity to riluzole.
URI
http://hdl.handle.net/10454/16574
Version
Accepted Manuscript
Citation
Sweeney JB, Rattray M, Pugh V and Powell LA (2018) Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis. ACS Medicinal Chemistry Letters. 9(6): 552-556.
Link to publisher’s version
https://doi.org/10.1021/acsmedchemlett.8b00103
Type
Letter
Notes
The full text will be available at the end of the publisher's embargo, 14th June 2019.
Collections